PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Aaron Diamond AIDS Research Center, Columbia University Irving Medical Center, New York, NY, USA.\', \'Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.\', \'Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.\', \'Department of Chemistry, Columbia University, New York, NY, USA.\', \'Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, USA.\', \'WuXi AppTec, Cambridge, MA, USA.\', \'Department of Biological Sciences, Columbia University, New York, NY, USA.\', \'Department of Chemistry, Columbia University, New York, NY, USA. bstockwell@columbia.edu.\', \'Department of Biological Sciences, Columbia University, New York, NY, USA. bstockwell@columbia.edu.\', \'Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, USA. ac4304@cumc.columbia.edu.\', \'Aaron Diamond AIDS Research Center, Columbia University Irving Medical Center, New York, NY, USA. dh2994@cumc.columbia.edu.\', \'Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA. dh2994@cumc.columbia.edu.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1038/s41467-021-22362-2
?:hasPublicationType
?:journal
  • Nature communications
is ?:pmid of
?:pmid
?:pmid
  • 33795671
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 6.582
?:rankingScore_hIndex
  • 198
?:title
  • Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all